mardi 6 novembre 2018

Onco Actu du 6 novembre 2018

1. Biologie

Breast cancer cells become invasive by changing their identity [Karolinska Institutet]

Relapsed leukemia flies under immune system’s radar [WUSTL]

1.4 Biologie - Technos

Upgraded computational tool boosts search for cancer vulnerabilities [Broad Institute]

3.1.1 Prévention - Tabac - e-cigs

Doctors don't know whether they should encourage smokers to switch to e-cigarettes [The Telegraph]

Teen vapers smoke just as much as youth who don't use e-cigarettes [Reuters]

4.12 Biopsies liquides

NCRI 2018: Using liquid biopsies to understand cancer treatment [institute of Cancer Research]

Blood Test Shows Promise for Detecting Genetic Changes in Brain Tumors [NCI]

4.3 Dép., diag. & prono. - Industriels

Illumina Buys PacBio: More Thoughts [Omics! Omics!]

5. Traitements

Ramirez: We no longer offer minimally invasive radical hysterectomy at MD Anderson [The Cancer Letter]

Minimally invasive surgery lowers survival in cervical cancer, new studies show [The Cancer Letter]

5.12.1 Immunothérapies - partenariats

Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines [Lilly]

After playing possum in I/O, Eli Lilly shows new signs of life with $40M-plus cash discovery deal for NextCure [EndPoints]

Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer [BMS]

5.12.8 Immunothérapies - Economie

Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL [Invectys]

5.2.1 Pharma - Partenariats

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

Pfizer snags OK for Xalkori follow-up Lorbrena in its 3rd cancer approval in 2 months [FiercePharma]

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC [FDA]

6.1 Observation

‘Morning people’ have lower breast cancer risk [BBC News]

6.12 Ethique

Cancer Society Executive Resigns Amid Upset Over Corporate Partnerships [NY Times

6.6 Publications

Wellcome is updating its open access policy [Wellcome]

In win for open access, two major funders won't cover publishing in hybrid journals [Science]

Peer Review: The Worst Way to Judge Research, Except for All the Others [NY Times]

Wellcome and Gates join bold European open-access plan [Nature]

6.7 DMP, Big Data & applis

Big Data Analysis Predicts Risk Of Radiotherapy Side Effects [NCRI]

6.7.1 IA/bioinformatique

First Blockchain-based Genomic Data Marketplace Launches [The Scientist]

6.7.3 DMP

Why Doctors Hate Their Computers [New Yorker]

6.8 Communication

When medicine & media sugarcoat the true impact of patient harms [HealthNewsReview]

6.9 Controverses

Evolution Revolution: CRISPR in Cancer Care [Cure]